Bipolar Disorder: Mood-Episode Cues, Lithium Surveillance & Agitation Escalation
Manic/hypomanic and depressive episode patterns for ward and community clinicians—therapy themes, toxicity monitoring for mood stabilisers, safety and escalation checkpoints.
Featured snippet
Bipolar disorder refers to cyclic mood episodes where people experience clinically significant mania or hypomania, usually interspersed with major depressive episodes (clinical guide to depression as a diagnostic neighbour); distinguishing bipolar II from recurrent unipolar depression remains a longitudinal task because hypomania is often retrospectively reconstructed.
Clinical snapshot: Once mania meets severity/duration thresholds, antimanic pharmacotherapy—not sleep hygiene alone—is the cornerstone; nurses prioritise sedation–airway balance, granular oral intake/fluid charts when neuroleptic loading occurs, toxicity surveillance for lithium and valproate, and reproducible suicidal ideation reassessment tied to multidisciplinary risk plans.
- Operationalise polarity with a longitudinal timeline: euphoria or sustained irritability, reduced subjective need for sleep, pressured speech or flight of ideas alongside functional impairment distinguishes mania from everyday stress—compare with contextual mood-swing cues and anxiety spectrum disorders that lack discrete multi-day polarity shifts.
- Antidepressant monotherapy carries mood-instability hazard in mislabelled bipolar depression; ensure psychiatry—not nursing—guides SSRI initiation; when prescribers add cover, reconcile antipsychotics and mood stabilisers through medication reconciliation alongside high-alert medication administration safeguards.
- Guideline pathways cluster mood stabilisers and second-generation antipsychotics (examples in our library include lamotrigine for maintenance/depression-heavy phenotypes where appropriate and quetiapine, olanzapine, aripiprazole, risperidone, carbamazepine frameworks per local formulary) with mandatory metabolic, movement-disorder and ECG stewardship where clinically indicated.
- Lithium & valproate toxicity windows broaden with dehydration, NSAIDs, renal injury, metabolic stress or pregnancy—baseline and interval electrolyte panels, eGFR tracking, and scheduled liver-function tests support safe continuation.
- Acute wards should pair therapeutic engagement with safety planning: clear thresholds for restraint application only after de-escalation bundle use, level-of-consciousness assessment when antipsychotic co-sedation stacks, and toxicology screens when substance mimicry is plausible.
⚡ Quick Facts
*Unless mood episode is sufficiently severe that inpatient care is warranted earlier—clinical diagnosis remains syndromic, not checklist-only.
💡 Clinical Pearl
ADHD overlays and stimulant context: Lifelong distractibility differs from episodic pressured speech spanning days with objectively reduced sleep need; collateral history from relatives often discloses adolescent hypomanic traces. Patients on prescription stimulants need psychiatry-informed attribution—withdrawal insomnia can masquerade as depression—yet never adjust stimulants at the bedside without formal review (ADHD in adults overview).
📋 Contents
What is Bipolar Disorder?
Bipolar disorder gathers chronic mood conditions in which clinically significant mood elevation (mania or hypomania) clusters in time-separated episodes alternating, for many patients, with major depressive episodes. Severity sits on a polarity gradient: euphoria or pervasive irritability, objective psychomotor acceleration, pressured language, reckless pleasure pursuits, inflated self-regard—or psychotic amplification with hallucinations—during mania contrasts with hypoenergy, hypersomnia or terminal insomnia, anhedonia, and neurovegetative slump during bipolar depression.
Neurobiology is multifactorial: high heritability estimates interact with developmental trauma, disrupted circadian routines, childbirth-related biological stress, inflammatory states, substance exposure, and iatrogenic antidepressant loading in predisposed circuits. Limbic–prefrontal network dysregulation, monoaminergic excess during mania versus relative inefficiency during depression, and mitochondrial or ion-channel hypotheses circulate in literature, yet bedside utility lies in behavioural pattern recognition and collateral-supported timelines rather than any single plausible mechanism.
Because hypomania can feel subjectively adaptive, patients often minimise early highs while emphasising misery in depressive phases—skewing outpatient charts toward recurrent depression unless clinicians (and inpatient nurses corroborating 24‑hour rhythms) quantify sleep need, speech rate and spend pattern across weeks.
Episode typing & DSM‑5 anchors
Formal diagnosis applies DSM‑5 polarity criteria—not momentary irritation—and tags specifiers clinicians should document verbatim in handoff summaries (peripartum onset, rapid cycling ≥4 discrete mood episodes in 12 months, mixed features despite dominant polarity, seasonal pattern, anxious distress, melancholic binge within depression where applicable).
| Label | Operational threshold | Nursing implication |
|---|---|---|
| Bipolar I disorder | ≥1 manic episode meeting duration/impairment or hospital mandate | Expect antimanic prescribing, potential capacity issues, sedation–hydration stewardship, safety hold discussions. |
| Bipolar II disorder | ≥1 hypomanic + ≥1 major depressive episode; no full manic history | Depressive readmissions dominate; antidepressant risks remain—watch mixed features. |
| Cyclothymic disorder | ≥2 years of numerous hypomanic & depressive symptoms failing full episode thresholds | Destabilisers (sleep shift work, recreational drugs) need tight counselling; psychotherapy slots critical. |
| Other specified bipolar | Clinician-defined short-duration hypomania or insufficient episode count documented | Still warrants mood‑stabiliser thinking when risks high—avoid dismissing unstable polar shifts. |
On a small screen, swipe or scroll sideways to see the full table.
ICD‑11 nomenclature aligns conceptually yet documentation systems differ—mirror the diagnosing psychiatrist wording to prevent reconciliation errors between inpatient and outpatient records.
Escalate immediately when any of the following coincide with suspected or known bipolar exacerbation:
- Active suicidal plan/intent with access (especially during mixed states or intoxication) or escalating self-injurious behaviour amid agitation.
- Early postpartum mania/psychosis in a patient whose chart documents prior bipolarity—coordinate obstetric liaison per local peripartum psychiatric pathway.
- Neuroleptic malignant syndrome suspicion (hyperthermia, lead-pipe rigidity, autonomic storm) or lithium toxicity encephalopathy with coarse tremor, diarrhoea, confusion—overlap delirium assessment.
- First manic presentation after middle age focal neurology deficits, unexplained seizure, or immune encephalitis phenotype—acute medical work-up precedes reassurance.
Immediate actions: Initiate organisational suicide protocol, summon senior psychiatry/medical colleagues, withhold further sedative stacking until airway reviewed, duplicate critical medication timing for pharmacy audit, arrange emergency labs/imaging directed by clinician, and ensure constant observation thresholds match risk tier.
Symptoms
Polymorphic expression depends on episode polarity, age, comorbidity load, and premorbid temperament; nurses compare current presentation with recent baseline instead of inferring illness from a single shift snapshot.
Manic / hypomanic semiology
- Euphoria or persistent irritability with outwardly observable psychomotor acceleration, reduced need for sleep without next-day fatigue, pressured or tangential speech, grandiosity, hypersexuality, impulsive spending, flight of ideas, easy distractibility.
- Psychotic overlap: mood-congruent delusions, command auditory phenomena—document safety implications without diagnostic speculation.
Depressive semiology (bipolar depression)
- Anhedonia, hypersomnia versus terminal insomnia paradox, psychomotor slowing, rumination worthlessness, carbohydrate craving, suicidal ideation—often deeper when mixed features lurk contemporaneously.
- Somatic amplifiers: migraine, gastrointestinal distress, pains without clear lesion—coordinate medical review rather than reflexively blaming “somatoform disorder.”
Atypical or high-risk nuances
- Rapid ultradian shifts within single days may flag mixed states even when formal mixed specifier incomplete.
- Postpartum or perimenstrual destabilisation—escalate early per obstetric/psychiatry joint pathways.
- Paediatric mania may masquerade as chronic irritability; developmental services often co-manage—avoid anchoring labels on one tantrum.
Causes and Risk Factors
Bipolar disorder reflects polygenic vulnerability interacting with sleep–wake disruption, early adversity, substance exposure, obstetric stress, inflammation, and medication-induced destabilisation—there is no single deterministic “chemical imbalance” target for ward education soundbites.
Non-modifiable contributors
- First-degree relative with bipolar spectrum illness (risk elevation not diagnostic certainty).
- Personal history of postpartum mania or psychosis—flags future pregnancies.
Modifiable or contextual precipitants
- Circadian disruption: shift work, jet lag, bright-light exposure at night—common destabilisers during acute admissions.
- Substances: stimulants, cannabis, alcohol withdrawal—history must screen polysubstance patterns (alcohol use disorder overview).
- Trauma sequelae: hyperarousal overlaps mania phenomenology—trauma-informed charting helps psychiatry separate PTSD from primary mood cycling.
- Antidepressant loading without antimanic cover in misdiagnosed bipolar depression—escalate when patients report “activation” after SSRI/SNRI starts; example agent monograph: escitalopram.
How is Bipolar Disorder Diagnosed?
Diagnosis is syndromic (DSM‑5/ICD‑11), longitudinal, and multidisciplinary—no single biomarker or imaging rule-out exists for routine practice.
Clinical assessment
Use collateral mood calendars, prior psychiatric records, childbirth history, forensic risk and capacity notes. Structured tools (e.g. MDQ, HMRS/MADRS variants in specialist services) support but do not replace expert synthesis.
Laboratory investigations
- Baseline and interval metabolic monitoring for antipsychotic/mood-stabiliser regimens—including renal indices when lithium contemplated.
- Thyroid and B12/folate grids when cognition atypical—hyperthyroidism can mimic anxiety-driven agitation whereas hypothyroidism deepens lethargic depression.
- Urine toxicology when acute presentation suggests sympathomimetic or withdrawal contribution.
Imaging
MRI/acute CT reserved for focal neurology, first manic episode beyond middle age, seizure, unexplained abrupt cognitive decrement—coordinate with liaison psychiatry/medical teams.
Diagnostic refinement & follow-up cadence
| Clinical scenario | Practice-facing review theme |
|---|---|
| New bipolar diagnosis discharged from acute ward | Community psychiatry ≤7–14 days depending on residual risk tiers; suicide prevention planning updated each contact. |
| Stable maintenance between episodes | Routine psychiatrist review often months apart—nurses in primary care reinforce sleep regularity between visits. |
| Therapy escalation or antidepressant introduction | Earlier nursing telephone triage (~3–10 days) to capture insomnia flip, jitteriness or racing thoughts signalling switch. |
| Valproate or lithium onboarding | Strict laboratory calendar per trust policy after each dose escalation until steady state clarified. |
On a small screen, swipe or scroll sideways to see the full table.
Clinical decision flow
High-yield triage logic for nurses; prescribing remains medical/psychiatric scope.
- Screen polarity first: quantify sleep need, speech rate, spend or sexual risk taking before attributing agitation solely to personality conflict.
- Rule out medical mimics: infection, hypoglycaemia, thyroid storm, substance intoxication/withdrawal—collate vitals, glucose, infection markers per pathway.
- Risk-stratify: suicidal ideation, infant in home, command hallucinations, domestic violence exposure—activate safeguarding plus psychiatry STAT.
- Stabilise milieu: low-stimulation environment, consistent nursing team, predictable medication times, limit caffeine after mid-afternoon.
- Referral triggers: first manic episode, pregnancy, treatment resistance, rapid cycling, severe kidney disease on lithium—document reason for specialist upgrade.
Differential diagnoses
Overlap is the rule; clarity emerges from timeline, treatment response, and collateral—not from one good day or one bad night.
| Alternative | Distinguishing cues |
|---|---|
| Major depressive disorder (unipolar) | No clear historic hypomanic/manic syndrome; antidepressant tolerance historically higher—still revisit if recurrent early “failed” antidepressant courses. |
| Borderline personality–pattern emotional lability | Mood shifts often hours-long, tightly linked to interpersonal triggers; sleep architecture less classically bipolar—diagnosis belongs to structured assessment, not bedside labels. |
| ADHD hyperfocus | State lasts situationally; lacks bioproductive nocturnal mania energy—compare with linked condition page when stimulants are in the chart. |
| Substance-induced mood disorder | Temporal lock to intoxication/withdrawal; repeat bedside toxicology and collateral when clinical picture shifts overnight. |
| Schizophrenia-spectrum primary psychosis | Mood symptoms secondary or brief relative to chronic positive symptoms—different antipsychotic dosing discussions; avoid casual cross-diagnosis. |
On a small screen, swipe or scroll sideways to see the full table.
Unipolar depression vs bipolar depression — charting clues
| Feature | Supports unipolar depression | Raises bipolar suspicion |
|---|---|---|
| Antidepressant response | Sustained remission without activation | Early “paradoxical” energy, insomnia flip, mixed symptoms |
| Sleep | Insomnia with fatigue | Hypersomnia prominent; or historic periods of little sleep without tiredness |
| Family history | Mood disorders non-specific | Relatives with hospitalised mania, postpartum psychosis |
| Age of first depression | Variable | Teen onset, postpartum first break, psychotic features |
On a small screen, swipe or scroll sideways to see the full table.
Treatment options
Multimodal plans combine pharmacotherapy, structured psychotherapy in stable phases, sleep regulation, substance cessation, obstetric liaison, and occupational rehabilitation—treatment failure often reflects partial adherence, pharmacokinetic interactions, or mis-specified episode type.
First-line pharmacologic themes (specialist-selected)
- Acute mania: lithium, valproate, carbamazepine-class options plus second-generation antipsychotics—monotherapy or combination per CANMAT/ISBD-style algorithms referenced below.
- Bipolar depression: quetiapine, lurasidone (where licensed), lamotrigine titration for maintenance/depressive prevention, adjunctive antidepressants only with antimanic cover and close monitoring.
- Maintenance: emphasise long-acting injectable antipsychotics or lithium when adherence or illness insight poor—requires enhanced laboratory cadence.
Psychosocial and nursing-co-delivered supports
- Psychoeducation groups, IPSRT-style interpersonal and social rhythm therapy, CBT adapted for bipolar depression when concordance allows.
- Care coordination for benefits, housing, child protection—social instability drives relapse as potently as pill gaps.
Special populations
- Pregnancy / reproductive potential: valproate largely contraindicated; lithium requires shared decision-making with maternal–fetal medicine; document contraception where mandated.
- Renal impairment: lithium often contraindicated or dose-minimised—creatinine/eGFR trending essential.
- Older adults: fall risk with sedating antipsychotics; QT monitoring; anticholinergic burden review.
Clinical Practice Considerations
Workflow anchors that keep teams aligned with guideline intent (NICE CG185, CANMAT/ISBD iterations) while respecting local formulary.
- Monitoring intervals: metabolic panel 12-weekly after antipsychotic stabilisation then at least annually if stable; lithium levels 5–7 days after each dose change then per trust schedule; more frequent levels during illness causing dehydration.
- Drug–drug vigilance: NSAIDs + ACE inhibitors + lithium = triple threat to renal handling; enzyme-inducing anticonvulsants alter oral contraceptive efficacy—escalate to pharmacist before patient assumes protection.
- Adherence appraisal: pharmacy refill data, pill organisers, long-acting injections; explore motivational—not punitive—barriers.
- Treatment failure criteria: two adequate-duration trials at therapeutic exposure without response, persistent mixed features, or incapacitating adverse effects—referral to tertiary mood disorder service.
- MDT roles: occupational therapy for overstimulation pacing, dietetics for olanzapine-associated weight gain, peer support for stigma reduction.
Possible complications
- Suicide completion—highest attributable risk often in depressive/mixed polarity with impulsivity and substance co-use.
- Metabolic syndrome, NAFLD, cerebrocardiovascular sequelae tied to chronic antipsychotic exposure plus lifestyle disruption.
- Neuroleptic malignant syndrome; lithium-associated nephrogenic diabetes insipidus, hypothyroidism; valproate hepatotoxicity or pancreatitis; lamotrigine Stevens–Johnson spectrum (rapid titration or interaction risk).
- Financial ruin, relationship breakdown, incarceration—document collateral psychosocial loss for safeguarding reviews.
Prevention
Genetic predisposition is not preventable, but relapse frequency and medical harm are modifiable with rigorous systems care.
- Maintain sleep regularity agreements post-discharge; flag night-shift return-to-work plans for occupational health input.
- Early recognition of prodromal insomnia or spending urges—activate self-management plans and crisis lines.
- Vaccination, dental and primary-care screening—people with SMI experience mortality gap partly from missed prevention.
Prognosis and Outlook
Many patients achieve inter-episode functioning with optimised pharmacotherapy and psychosocial scaffolding; prognosis darkens with treatment delay, substance persistence, domestic chaos, or metabolic complications—transparent communication improves engagement without false certainty.
- Rapid cycling or cognitive decline patterns warrant assertive community treatment models.
- Functional recovery may lag mood syndromes—vocational rehab remains valuable months after symptoms remit.
In Clinical Practice…
- Shift-to-shift mood scoring (0–10 energy, irritability, sleep hours) creates objective trends families and clinicians trust.
- Replace judgmental language (“non-compliant”, “attention-seeking”) with behaviourally specific descriptors tied to safety.
- Interpreter access for reproductive-risk counselling; never assume silent nod equals understanding of teratogen plans.
- Quietly assess financial exploitation when grandiose gifting or online spending resumes—safeguarding referral.
Bedside monitoring checklist
- Vitals & observation level: q-shift if high suicide/mixed risk; note temperature if NMS considered.
- Neuropsychiatric screen: speech rate, flight of ideas, persecutory content, command hallucinations, insight.
- Fluid & nutrition: oral intake if sedated; glucose if antipsychotic-naïve patient starting olanzapine/quetiapine-heavy regimens.
- Movement exam: parkinsonism, akathisia, ocular flutter—early IM anticholinergics only if ordered.
- Labs due today: lithium level timing (trough), valproate level if policy-based, ECG if QT-prolonging stack.
When to Seek Emergency Care
- Imminent suicidal or homicidal plan with means, or attempted self-ligature/hanging.
- Malignant catatonia, stupor with dehydration, refusal of all fluids linked to profound psychosis.
- Suspected lithium toxicity (ataxia, coarse tremor, diarrhoea, confusion) or NMS as above.
- Postpartum psychosis with infant safety concern.
- Acute medical instability (sepsis, hypertensive emergency) masquerading as “psychiatric behavioural crisis.”
Activate emergency medical services or internal medical emergency team per protocol while maintaining least-restrictive engagement.
Clinical signs of deterioration & escalation
Symptomatic red flags
- Escalating goal-directed behaviours (spending sprees resumed, sexual disinhibition disclosures).
- Insomnia creeping earlier each night preceding full mania—historically reliable prodrome for that individual.
- Depressive deepening with pronounced anhedonia, giving away possessions, farewell gestures.
Objective escalation cues
- Rising lithium level or creatinine without clear hydration correction.
- QTc drift on telemetry after adding multiple sedating drugs—pharmacy review.
- Worsening hyponatraemia on carbamazepine or SSRI co-administration pathways.
Escalate to senior nursing/psychiatry when observation level no longer matches risk, when PRN sedative stacking exceeds Standing orders, or when medical screens remain abnormal despite reassurance attempts.
Nursing management
Pre-treatment / admission
- Capture weapon access, child/dependent safeguarding, financial power-of-attorney status when capacity fluctuates.
- Upload prior advance decisions or community treatment orders when legally applicable.
During acute stabilisation
- Pair chemical calm with sensory modulation—dim lights, lower ward noise, predictable nursing assignments.
- Offer nicotine replacement ethically where smoking cessation simultaneous with psychiatric crisis is unrealistic without plan.
Medication administration & education
- Use teach-back on late-onset rash with lamotrigine, sedation driving warnings, contraception mandates with teratogens.
- Never crush enteric-coated valproate or alter lithium formulations without pharmacy—bioavailability swings risk toxicity or breakthrough mania.
Evaluation
- Measure outcomes through episode-free days, readmission intervals, metabolic indices, patient-reported function—not symptom scores alone.
NCLEX practice questions
These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of bipolar I / II disorder, lithium / valproate / atypical-antipsychotic stewardship, lithium-toxicity surveillance and the suicide / manic-relapse pathway.
Unfolding case (Questions 1–3): Ms. N., 28 with bipolar I disorder on lithium 800 mg daily, presents with a 2-week history of elevated mood, decreased need for sleep (3 hours), grandiosity, pressured speech, increased spending and risky sexual behaviour. She has stopped taking her lithium and recently started an SSRI for low mood. PHQ-9 4, YMRS 28. She denies suicidal ideation. Lithium level 0.4 mmol/L.
Answer key & rationale
How soon after a mood-stabiliser or antipsychotic change should nursing review symptoms and vitals?
Document sleep, energy, speech rate, irritability, appetite, and any movement side effects within 72 hours of each titration step; align exact vital–ECG policies with pharmacy for drugs that prolong QT; escalate sooner if food/fluid intake collapses or behaviour becomes dangerous.
Why is antidepressant monotherapy a concern in suspected bipolar depression?
Unopposed antidepressants can precipitate mood switching or mixed features in vulnerable patients—psychiatry usually pairs antidepressants with anti-manic cover or avoids them; nurses should not coach patients to start or stop agents without prescriber direction.
Which laboratory tests typically accompany lithium therapy?
Protocols nearly always combine lithium level timing with renal function—creatinine/eGFR pattern—and electrolytes including sodium; thyroid function surveillance is longitudinal; CBC or additional panels follow local mental health formulary grids.
When should lithium levels be repeated after a dehydration illness?
Any gastroenteritis, diuretic change, NSAID initiation, or low oral intake raises toxicity risk—request prescriber review and level check per pathway rather than guessing intervals.
What red flags differentiate agitated mania from stimulant intoxication alone?
History corroborating sleep need reduction, expansive grandiosity across weeks, prior episodic course, or family bipolar history favour primary mood episodes—yet urine toxicology and medical screens remain essential before attributing causality.
How often should suicidal ideation be reassessed during an acute mood episode?
Psychiatric services often reassess protective factors and lethality whenever presentation changes, within hours of shifts on acute wards, after any visitor contact that upsets the patient, and after medication adjustments that alter arousal.
What monitoring supports valproate safety beyond pregnancy prohibition counselling?
Track somnolence, tremor, bleeding or bruising, abdominal pain suggesting pancreatitis picture, ammonia-related encephalopathy signals, and LFT abnormalities per scheduled labs—immediate senior review when alertness drops unexpectedly.
Can primary-care style sleep improvement advice substitute for antimanic therapy?
Sleep hygiene complements care but cannot replace mood-stabiliser or antipsychotic plans when manic criteria are met; worsening insomnia despite routine measures warrants psychiatric reassessment.
What documentation speeds safe handoff for bipolar admissions?
Capture episode polarity, collateral mood timeline, substances, allergies, reproductive status, contraception regimen, lithium/valproate levels with dates, ECG QT issues, restraint history, and crisis contacts verbatim from the multidisciplinary team sheet.
When is neurology referral considered alongside bipolar care?
First presentation of manic symptoms after age 50, abnormal focal neurologic examination, unexplained seizure, abrupt cognitive decline warrant neuroimaging/neurology input to exclude structural or autoimmune mimics—not every stable bipolar relapse.
- National Institute for Health and Care Excellence (NICE). Bipolar disorder: assessment and management (CG185).nice.org.uk/guidance/cg185
- National Institute of Mental Health (NIMH). Bipolar disorder health topic.nimh.nih.gov/health/topics/bipolar-disorder
- National Institute of Mental Health (NIMH). Bipolar disorder statistics.nimh.nih.gov/health/statistics/bipolar-disorder
- Jain A, Mitra P. Bipolar disorder. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.ncbi.nlm.nih.gov/books/NBK558998
- Agency for Healthcare Research and Quality. McDonagh MS, et al. Treatment for bipolar disorder in adults: a systematic review (Comparative Effectiveness Review No. 208).ncbi.nlm.nih.gov/books/NBK532193
- Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018.pubmed.ncbi.nlm.nih.gov/29536616
- Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013.pubmed.ncbi.nlm.nih.gov/23663941
- NHS (UK). Bipolar disorder overview.nhs.uk/mental-health/conditions/bipolar-disorder/overview
- Merck Manual Professional. Bipolar disorders.merckmanuals.com/professional/psychiatric-disorders/mood-disorders/bipolar-disorders
- Royal College of Psychiatrists (UK). Bipolar disorder information.rcpsych.ac.uk/mental-health/problems-disorders/bipolar-disorder
- MedlinePlus (NLM). Bipolar disorder.medlineplus.gov/bipolardisorder.html
- U.S. Food and Drug Administration. Information on valproate products (Depakote, Depakote ER, Depakene, Depacon, generics).fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-valproate-sodium-or-divalproex-sodium-depakote-depakote-er-depakene-depacon-and